A client develops severe diarrhea, mucositis, neutropenia, and neurotoxicity during the first treatment cycle of capecitabine. Which action is the priority?
1Treat the severe gastrointestinal, marrow, and neurologic effects as an expected first-cycle response and continue treatment.
2Give the next scheduled dose with an antidiarrheal, then contact oncology if symptoms persist for another 24 hours.
3Hold further doses and notify oncology urgently for evaluation of early severe fluoropyrimidine toxicity and possible DPD deficiency.✓ Correct answer
4Wait for the scheduled cycle review while encouraging oral fluids and recording the daily number of stools.
Explanation
Acute early-onset or unusually severe toxicity can indicate complete or near-complete dihydropyrimidine dehydrogenase deficiency. Further exposure can be fatal and requires immediate interruption and evaluation.
Quick answer Treat early multisystem capecitabine toxicity as a stop signal.
Why this is correct Supportive treatment does not make continued fluoropyrimidine exposure safe while severe toxicity is being evaluated.
Easy analogy or mental picture Build a medication-safety chain: identify the new cue, connect it to the drug mechanism or labeled limitation, stop preventable exposure, stabilize the client, and verify a measurable response.
Memory hook Drug, urgent cue, protective action, and reassessment endpoint.
NCLEX decision rule Choose the action that prevents the most immediate medication-related harm while preserving indicated treatment and required monitoring.
Why the other choices are wrong Options that continue a suspect exposure, normalize a labeled danger cue, substitute an unauthorized dose, or delay escalation leave the client at risk.
References
1DailyMed: Capecitabine TabletsDPD deficiency and early severe or fatal fluoropyrimidine toxicity
Medication-safety reviewVerify indication, current assessment, dose and route, organ function, interactions, urgent toxicity cues, authorized action, and measurable follow-up.